Results 221 to 230 of about 1,365,106 (309)

Exploring new avenues: Psychedelic‐assisted therapy for young people

British Journal of Clinical Pharmacology, EarlyView.
Rates of mental illness in young people are increasing, whereas the development of novel mental health treatments has not significantly progressed. Psychedelic‐assisted therapy, using substances such as psilocybin and 3,4‐methylenedioxymethamphetamine (MDMA), has shown potential in the treatment of mental illnesses in the adult population, including ...
Ioanna Artemis Vamvakopoulou, Dasha Nicholls, David J. Nutt, Martina Di Simplicio   +3 more
wiley   +1 more source

Utilization of Fertility Treatment in Japan During the First Year of Insurance Coverage: Analysis of Real-World Health Claims Data. [PDF]

Reprod Med Biol
Okawara M, Kuwazuru T, Masunaga M, Fujimoto K, Nagata M, Iwasa T, Fujino Y.   +6 more
europepmc   +1 more source

Utilization of immune checkpoint inhibitors for the treatment of cancer in Scotland, 2018–2024: A national retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
Aims The aim of the study is to describe the use of immune checkpoint inhibitors (ICIs) for the treatment of cancer in Scotland. Methods The retrospective observational cohort study included patients aged 18 years or older who commenced treatment with an ICI in Scotland between 1 January 2018 and 31 December 2024.
Tanja Mueller, Christine Crearie, Liya Lu, Jiafeng Pan, Fraser N. Sneden, David Martin, Amanj Kurdi, Catherine S. Thomson, Julie Clarke, Marion Bennie   +9 more
wiley   +1 more source

Changes in Prescription Patterns and Diagnostic Outcomes of Polysomnography After Insurance Coverage: A Multicenter Retrospective Study. [PDF]

J Rhinol
Park DY, Cho JH, Park CS, Koh TK, Koo SK, Kim SW, Kim SJ, Kim YM, Kim JW, Kim JY, Kim HJ, Doo JG, Moon JW, Park MJ, Park SW, Park SI, Park S, Bae MR, Seo MY, Ahn SH, Yang HC, Lee KH, Lee SH, Lee YH, Lee EJ, Jun YJ, Jeon YJ, Chung YS, Chung J, Cho KS, Cho SW, Jo YS, Chae HS, Choi IS, Choi JH, Han SC.   +35 more
europepmc   +1 more source

Impact of parameter settings on the estimation of drug exposure with the individualized dispensing patterns method

British Journal of Clinical Pharmacology, EarlyView.
Aim To assess the impact of parameter settings when using the individualized dispensing patterns (IDP) method to estimate exposure duration from dispensing data. Methods We conducted a cohort study using a 2% representative sample of the French healthcare insurance database from 2013 to 2022.
Laëtitia Gosselin, Clara Lévy, Noémie Sève, Thierry Blanchon, Marianne Sarazin, Louise Rossignol, Maryse Lapeyre‐Mestre, Nathanaël Lapidus, Olivier Steichen   +8 more
wiley   +1 more source

Medicaid expansion for undocumented adults and its association with health insurance coverage among noncitizens in California, 2017-2023. [PDF]

Health Aff Sch
Guadamuz JS, Chen S, Bustamante AV.
europepmc   +1 more source

Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real‐world data

British Journal of Clinical Pharmacology, EarlyView.
Aims The glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) semaglutide and liraglutide are approved for chronic weight management. Both drugs also have favourable effects on the risk of developing diabetes and cardiovascular disease (CVD) compared with placebo, but their comparative effectiveness for these outcomes is unclear.
Ethan J. Cannon, Wendy Wang, Faye L. Norby, Rob F. Walker, Shalini Kulasingam, Lisa S. Chow, Joel F. Farley, Pamela L. Lutsey   +7 more
wiley   +1 more source

Health Insurance Coverage and Income Inequality in the United States: Findings from the American Community Survey, 2010 to 2023. [PDF]

Inquiry
Molina-Salazar RE, Carbajal-De-Nova C.
europepmc   +1 more source

Trends in publicly subsidized and private access to GLP‐1 medicines indicated for type 2 diabetes in Australia, 2020–2025

British Journal of Clinical Pharmacology, EarlyView.
Aims GLP‐1 medicines provide substantial cardio‐renal benefits for type 2 diabetes (T2D) and are increasingly used for weight loss. Most high‐income countries subsidize access for T2D with restrictions; use outside of these restrictions occurs through private prescriptions. Despite strong consumer demand, the extent of private access to GLP‐1 medicines
Michael O. Falster, Juliana de Oliveira Costa, Tamara Y. Milder, Joanne Carson, Cade Shadbolt, Brendon L. Neuen, Clare Arnott, Andrew Wilson, Min Jun, Nicole Pratt, Sallie‐Anne Pearson   +10 more
wiley   +1 more source